Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option

MT Newswires Live12-04

Biogen (BIIB) said Wednesday that new trial analyses of Leqembi indicated that starting and continuing treatment early in Alzheimer's may keep patients at milder stages for longer and supported a subcutaneous dosing option for initiation.

Looking over a 10-year period using data from the Clarity AD extension and other antibody studies, the company estimated that people on long-term Leqembi stayed in earlier disease stages several years longer than a matched group without treatment.

For patients who began therapy with lower brain amyloid levels, the projections suggested the shift from early symptoms to moderate Alzheimer's could be pushed back by up to 8.3 years, compared with modeled progression without the drug, the company said.

The company also reported fewer systemic infusion reactions in patients switched to the injection regimen, low levels of anti-drug antibodies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588114000?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-04 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588114000","market":"hk","top_or_hot":-1,"title":"Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option","media":"MT Newswires Live","content":"<html><body><p> Biogen (BIIB) said Wednesday that new trial analyses of Leqembi indicated that starting and continuing treatment early in Alzheimer's may keep patients at milder stages for longer and supported a subcutaneous dosing option for initiation.</p><p>Looking over a 10-year period using data from the Clarity AD extension and other antibody studies, the company estimated that people on long-term Leqembi stayed in earlier disease stages several years longer than a matched group without treatment.</p><p>For patients who began therapy with lower brain amyloid levels, the projections suggested the shift from early symptoms to moderate Alzheimer's could be pushed back by up to 8.3 years, compared with modeled progression without the drug, the company said.</p><p>The company also reported fewer systemic infusion reactions in patients switched to the injection regimen, low levels of anti-drug antibodies.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-04 17:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biogen (BIIB) said Wednesday that new trial analyses of Leqembi indicated that starting and continuing treatment early in Alzheimer's may keep patients at milder stages for longer and supported a subcutaneous dosing option for initiation.</p><p>Looking over a 10-year period using data from the Clarity AD extension and other antibody studies, the company estimated that people on long-term Leqembi stayed in earlier disease stages several years longer than a matched group without treatment.</p><p>For patients who began therapy with lower brain amyloid levels, the projections suggested the shift from early symptoms to moderate Alzheimer's could be pushed back by up to 8.3 years, compared with modeled progression without the drug, the company said.</p><p>The company also reported fewer systemic infusion reactions in patients switched to the injection regimen, low levels of anti-drug antibodies.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B894F039.SGD","symbol_name":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2588114000","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588114000","pubTimestamp":1764841615,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biogen  said Wednesday that new trial analyses of Leqembi indicated that starting and continuing treatment early in Alzheimer's may keep patients at milder stages for longer and supported a subcutaneous dosing option for initiation.Looking over a 10-year period using data from the Clarity AD extension and other antibody studies, the company estimated that people on long-term Leqembi stayed in earlier disease stages several years longer than a matched group without treatment.For patients who began therapy with lower brain amyloid levels, the projections suggested the shift from early symptoms to moderate Alzheimer's could be pushed back by up to 8.3 years, compared with modeled progression without the drug, the company said.The company also reported fewer systemic infusion reactions in patients switched to the injection regimen, low levels of anti-drug antibodies.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BIIB":"渤健公司","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD"},"translate_title":"Biogen分享了关于减缓阿尔茨海默病进展的新Leqembi数据，注射选项","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1.5},"content_text":"Biogen (BIIB) said Wednesday that new trial analyses of Leqembi indicated that starting and continuing treatment early in Alzheimer's may keep patients at milder stages for longer and supported a subcutaneous dosing option for initiation.Looking over a 10-year period using data from the Clarity AD extension and other antibody studies, the company estimated that people on long-term Leqembi stayed in earlier disease stages several years longer than a matched group without treatment.For patients who began therapy with lower brain amyloid levels, the projections suggested the shift from early symptoms to moderate Alzheimer's could be pushed back by up to 8.3 years, compared with modeled progression without the drug, the company said.The company also reported fewer systemic infusion reactions in patients switched to the injection regimen, low levels of anti-drug antibodies.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588114000","isCrawlerRequest":true}